Description: Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines without preservatives, which completed phase III clinical trials. In addition, it exports its products. The company was founded in 2004 and is based in Chengdu, China.
Home Page: www.kangh.com
No. 182, Beijing Road
Chengdu,
610100
China
Phone:
86 28 8484 6555
Officers
| Name | Title |
|---|---|
| Mr. Qinghan Wang | GM & Director |
| Mr. Mingtai Tang | Deputy GM & CFO |
| Mr. Wenli Hou | Deputy GM & Director |
| Mr. Huaigong Chen | Deputy GM & Quality Mang. |
Exchange: SHE
Country: CN
Currency: Renminbi (¥)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 16.3192 |
| Price-to-Book MRQ: | 4.0497 |
| Price-to-Sales TTM: | 7.4937 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 588 |